Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xianjun Yu

Showing results (321-330 of 421) with videos related to

Pageof 43
Sort By:
Current Oncology (Toronto, Ont.)|February 24, 2023
Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal AdenocarcinomaYusheng Chen, Xuan Zou, Mingjian Ma, et al.
Clinical and Translational Medicine|August 30, 2021
Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancerZheng Zhang, Shunrong Ji, Qiangsheng Hu, et al.
Translational Oncology|March 8, 2025
The pancreatitis-cancer transformation-related factor, human rhomboid family-1, promotes pancreatic cancer progression through the SRC/YAP signaling pathwayZhilong Ma, Jie Hua, Miaoyan Wei, et al.
Oncology Letters|March 31, 2017
Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patientsGuopei Luo, Kaizhou Jin, Meng Guo, et al.
Cancer Management and Research|May 23, 2019
The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinomaShuo Li, Huaxiang Xu, Wenquan Wang, et al.
Experimental and Therapeutic Medicine|October 23, 2020
Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreasShengming Deng, Zhiyao Fan, Yitao Gong, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 13, 2026
Vorinostat Potentiates Chemoimmunotherapy in Immune-Enriched Pancreatic CancerChen Chen, Dingru Li, Yingna Liao, et al.
Molecular Medicine Reports|April 29, 2016
Critical role of oncogenic KRAS in pancreatic cancer (Review)Jiang Liu, Shunrong Ji, Chen Liang, et al.
Gut|August 4, 2023
CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinomaXiaomeng Liu, Rong Tang, Jin Xu, et al.
Journal of Immunology Research|August 1, 2022
Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal AdenocarcinomaYunzhen Qian, Yitao Gong, Yu Liu, et al.
Pageof 43

Showing results (321-330 of 421) with videos related to

Sort By:
Pageof 43
Current Oncology (Toronto, Ont.)|February 24, 2023
Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal AdenocarcinomaYusheng Chen, Xuan Zou, Mingjian Ma, et al.
Clinical and Translational Medicine|August 30, 2021
Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancerZheng Zhang, Shunrong Ji, Qiangsheng Hu, et al.
Translational Oncology|March 8, 2025
The pancreatitis-cancer transformation-related factor, human rhomboid family-1, promotes pancreatic cancer progression through the SRC/YAP signaling pathwayZhilong Ma, Jie Hua, Miaoyan Wei, et al.
Oncology Letters|March 31, 2017
Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patientsGuopei Luo, Kaizhou Jin, Meng Guo, et al.
Cancer Management and Research|May 23, 2019
The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinomaShuo Li, Huaxiang Xu, Wenquan Wang, et al.
Experimental and Therapeutic Medicine|October 23, 2020
Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreasShengming Deng, Zhiyao Fan, Yitao Gong, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 13, 2026
Vorinostat Potentiates Chemoimmunotherapy in Immune-Enriched Pancreatic CancerChen Chen, Dingru Li, Yingna Liao, et al.
Molecular Medicine Reports|April 29, 2016
Critical role of oncogenic KRAS in pancreatic cancer (Review)Jiang Liu, Shunrong Ji, Chen Liang, et al.
Gut|August 4, 2023
CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinomaXiaomeng Liu, Rong Tang, Jin Xu, et al.
Journal of Immunology Research|August 1, 2022
Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal AdenocarcinomaYunzhen Qian, Yitao Gong, Yu Liu, et al.
Pageof 43